The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts

Clinical Infectious Diseases

Volumn 58, Issue 2, 2014, Pages 214-224

  Memoli, Matthew J ^a   Athota, Rani ^a   Reed, Susan ^a   Czajkowski, Lindsay ^a   Bristol, Tyler ^a   Proudfoot, Kathleen ^a   Hagey, Rachel ^a   Voell, Jocelyn ^b   Fiorentino, Charles ^b   Ademposi, Angela ^c   Shoham, Shmuel ^d   Taubenberger, Jeffery K ^a  

^a Viral Pathogenesis and Evolution Section   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunocompromised host; Influenza; Influenza A; Stem cell transplant

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPING TECHNIQUE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE; NOSE SMEAR; PRIORITY JOURNAL; SERUM; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS SHEDDING; YOUNG ADULT;

IMMUNOCOMPROMISED HOST; INFLUENZA; INFLUENZA A; STEM CELL TRANSPLANT;

ADOLESCENT; ADULT; AGED; CYTOKINES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASAL MUCOSA; PATIENT OUTCOME ASSESSMENT; PROSPECTIVE STUDIES; SERUM; VIRUS SHEDDING; YOUNG ADULT;

EID: 84891808523     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit725     Document Type: Article

References (32)

1. WHO/UNAIDS/UNICEF. Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access 2011. 2011
2. Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: A population-based cohort study. Mayo Clin Proc 2009; 84:16-22
3. Chinen J, Buckley RH. Transplantation immunology: Solid organ and bone marrow. J Allergy Clin Immunol 2010; 125:S324-35
4. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: A global perspective. JAMA 2010; 303:1617-24
5. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-6
6. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000; 31:604-6
7. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990; 98:33-7
8. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis 1997; 24:1095-9
9. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010; 115:1331-42
10. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: Risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39: 1300-6
11. Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011; 32:471-93
12. Malavaud S, Malavaud B, Sandres K, et al. Nosocomial outbreak of influenza virus A (H3N2) infection in a solid organ transplant department. Transplantation 2001; 72:535-7
13. Vilchez RA, Fung JJ, Kusne S. Influenza A myocarditis developing in an adult liver transplant recipient despite vaccination: A case report and review of the literature. Transplantation 2000; 70:543-5
14. Embrey RP, Geist LJ. Influenza A pneumonitis following treatment of acute cardiac allograft rejection with murine monoclonal anti-CD3 antibody (OKT3). Chest 1995; 108:1456-9
15. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: A multicentre cohort study. Lancet Infect Dis 2010; 10:521-6
16. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: Hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 2007; 28:222-42
17. Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: Clinical features and association with bronchiolitis obliterans syndrome. Chest 2001; 119:1277-80
18. Faul JL, Akindipe OA, Berry GJ, Theodore J. Influenza pneumonia in a paediatric lung transplant recipient. Transpl Int 2000; 13:79-81
19. Shetty AK, Ross GA, Pranikoff T, et al. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplant 2012; 16:E153-7
20. Rocha E, Cox NJ, Black RA, Harmon MW, Harrison CJ, Kendal AP. Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J Virol 1991; 65:2340-50
21. Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host. J Infect Dis 2010; 201:1397-403
22. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- And peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-5
23. Memoli MJ, Bristol T, Proudfoot KE, Davis AS, Dunham EJ, Taubenberger JK. In vivo evaluation of pathogenicity and transmissibility of influenza A(H1N1)pdm09 hemagglutinin receptor binding domain 222 intrahost variants isolated from a single immunocompromised patient. Virology 2012; 428:21-9
24. McMinn P, Carrello A, Cole C, Baker D, Hampson A. Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community. Clin Infect Dis 1999; 29:456-8
25. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 2006; 193:760-4
26. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrugresistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-61
27. Nishikawa F, Sugiyama T. Direct isolation of H1N2 recombinant virus from a throat swab of a patient simultaneously infected with H1N1 and H3N2 influenza Aviruses. J Clin Microbiol 1983; 18:425-7
28. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128:597-602
29. Krafft AE, Russell KL, Hawksworth AW, et al. Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification. J Clin Microbiol 2005; 43:1768-75
30. Novel H1N1 Flu: Facts and Figures. 2009. Available at: Http://www.cdc. gov/H1N1FLU/Surveillanceqa.htm. Accessed 10 August 2013
31. Haran JP, Buglione-Corbett R, Lu S. Cytokine markers as predictors of type of respiratory infection in patients during the influenza season. Am J Emerg Med 2013; 31:816-21
32. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 32-5